In silico discovery of 2-amino-4-(2,4-dihydroxyphenyl)thiazoles as novel inhibitors of DNA gyrase B.

Cyclothialidines are a class of bacterial DNA gyrase B (GyrB) subunit inhibitors, targeting its ATP-binding site. Starting from the available structural information on cyclothialidine GR122222X (2), an in silico virtual screening campaign was designed combining molecular docking calculations with three-dimensional structure-based pharmacophore information. A novel class of 2-amino-4-(2,4-dihydroxyphenyl)thiazole based inhibitors (5-9) with low micromolar antigyrase activity was discovered.

[1]  Finton Sirockin,et al.  Functionality maps of the ATP binding site of DNA gyrase B: generation of a consensus model of ligand binding. , 2004, Journal of medicinal chemistry.

[2]  J. Champoux.  DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.

[3]  P. Charifson,et al.  Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. , 2008, Journal of medicinal chemistry.

[4]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[5]  F. Theil,et al.  New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine. , 2004, Journal of medicinal chemistry.

[6]  R. Jerala,et al.  Characterization of quercetin binding site on DNA gyrase. , 2003, Biochemical and biophysical research communications.

[7]  C V Smith,et al.  The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X‐ray crystallography. , 1996, The EMBO journal.

[8]  T. Self,et al.  Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. , 1996, The Journal of family practice.

[9]  T. Šolmajer,et al.  Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. , 2007, Current medicinal chemistry.

[10]  J. Rudolph,et al.  seco-Cyclothialidines: new concise synthesis, inhibitory activity toward bacterial and human DNA topoisomerases, and antibacterial properties. , 2001, Journal of medicinal chemistry.

[11]  M. Pucci,et al.  Recent advances in bacterial topoisomerase inhibitors. , 2008, Current opinion in pharmacology.

[12]  C. V. Smith,et al.  Mode of action of GR122222X, a novel inhibitor of bacterial DNA gyrase , 1996, Antimicrobial agents and chemotherapy.

[13]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[14]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[15]  T. Lübbers,et al.  Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[16]  A. Maxwell.  DNA gyrase as a drug target. , 1997, Trends in microbiology.

[17]  T. Šolmajer,et al.  Binding free energy calculations of N-sulphonyl-glutamic acid inhibitors of MurD ligase , 2009, Journal of molecular modeling.

[18]  K. Nagai,et al.  Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives. , 2004, Journal of medicinal chemistry.

[19]  G. Wolber,et al.  Discovery of novel benzene 1,3-dicarboxylic acid inhibitors of bacterial MurD and MurE ligases by structure-based virtual screening approach. , 2009, Bioorganic & medicinal chemistry letters.

[20]  P. Tsvetkov,et al.  DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5'-methyl group of the noviose. , 2002, Biochemistry.

[21]  M. Arisawa,et al.  Biological characterization of cyclothialidine, a new DNA gyrase inhibitor , 1993, Antimicrobial Agents and Chemotherapy.

[22]  Anthony Maxwell,et al.  The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. , 2003, Current topics in medicinal chemistry.

[23]  X. Barril,et al.  Structure-based discovery of a new class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[24]  H. Gmuender,et al.  Cyclothialidine and its congeners: a new class of DNA gyrase inhibitors. , 1993, Pharmacology & therapeutics.

[25]  C. Chung,et al.  Effect of detergent on "promiscuous" inhibitors. , 2003, Journal of medicinal chemistry.

[26]  L. Silver.  Does the cell wall of bacteria remain a viable source of targets for novel antibiotics? , 2006, Biochemical pharmacology.

[27]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[28]  G. Orphanides,et al.  Probing the binding of coumarins and cyclothialidines to DNA gyrase. , 1999, Biochemistry.

[29]  M. Arisawa,et al.  Characterization of the Binding Site for Cyclothialidine on the B Subunit of DNA Gyrase (*) , 1995, The Journal of Biological Chemistry.

[30]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[31]  Simona Golic Grdadolnik,et al.  In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[32]  Andrew J Lamb,et al.  Antimicrobial activity of flavonoids , 2005, International Journal of Antimicrobial Agents.

[33]  Eric D Brown,et al.  New targets and screening approaches in antimicrobial drug discovery. , 2005, Chemical reviews.